Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, 8093, Switzerland.
Yale Cancer Biology Institute, Yale University, West Haven, CT, 06516, USA.
Proteomics. 2019 Jul;19(13):e1800438. doi: 10.1002/pmic.201800438. Epub 2019 Jun 14.
CRISPR-Cas gene editing holds substantial promise in many biomedical disciplines and basic research. Due to the important functional implications of non-histone chromosomal protein HMG-14 (HMGN1) in regulating chromatin structure and tumor immunity, gene knockout of HMGN1 is performed by CRISPR in cancer cells and the following proteomic regulation events are studied. In particular, DIA mass spectrometry (DIA-MS) is utilized, and more than 6200 proteins (protein- FDR 1%) and more than 82 000 peptide precursors are reproducibly measured in the single MS shots of 2 h. HMGN1 protein deletion is confidently verified by DIA-MS in all of the clone- and dish- replicates following CRISPR. Statistical analysis reveals 147 proteins change their expressions significantly after HMGN1 knockout. Functional annotation and enrichment analysis indicate the deletion of HMGN1 induces histone inactivation, various stress pathways, remodeling of extracellular proteomes, cell proliferation, as well as immune regulation processes such as complement and coagulation cascade and interferon alpha/ gamma response in cancer cells. These results shed new lights on the cellular functions of HMGN1. It is suggested that DIA-MS can be reliably used as a rapid, robust, and cost-effective proteomic-screening tool to assess the outcome of the CRISPR experiments.
CRISPR-Cas 基因编辑在许多生物医学学科和基础研究中具有巨大的潜力。由于非组蛋白染色体蛋白 HMG-14(HMGN1)在调节染色质结构和肿瘤免疫方面的重要功能意义,CRISPR 在癌细胞中对 HMGN1 进行基因敲除,并研究随后的蛋白质组调节事件。特别是,使用 DIA 质谱法(DIA-MS),在 2 小时的单个 MS 拍摄中可重复性地测量超过 6200 种蛋白质(蛋白质-FDR 1%)和超过 82000 个肽前体。在 CRISPR 之后的所有克隆和培养皿重复实验中,DIA-MS 都可以可靠地验证 HMGN1 蛋白缺失。统计分析显示,HMGN1 敲除后有 147 种蛋白质的表达发生显著变化。功能注释和富集分析表明,HMGN1 的缺失诱导了组蛋白失活、各种应激途径、细胞外蛋白质组的重塑、细胞增殖以及补体和凝血级联和干扰素α/γ反应等免疫调节过程。这些结果为 HMGN1 的细胞功能提供了新的认识。建议 DIA-MS 可以可靠地用作快速、强大且具有成本效益的蛋白质组筛选工具,以评估 CRISPR 实验的结果。